Thymosin Alpha 1 — Research Compound

Thymosin Alpha 1 (Tα1) is a 28-amino acid immunomodulatory peptide originally derived from thymic tissue. Its synthetic analog, thymalfasin (Zadaxin), is FDA-approved for orphan indications such as malignant melanoma, chronic hepatitis B, DiGeorge syndrome, and hepatocellular carcinoma.

Ta1 is an intrinsically disordered protein, adopting a flexible two-helical structure with an unstructured loop under specific conditions, allowing promiscuous binding to multiple cellular targets. It acts as a cellular sensor, modulating immune responses in diverse physiological and pathological contexts.

Benefits May Include:

• Cell Maturation: Increases CD4+ and CD8+ Tcell counts and functionality
• COVID-19 Support: Improved survival and T-cell recovery in severe cases
• Cancer Outcomes: Enhanced survival in hepatocellular carcinoma; tumor cell apoptosis
• Vaccine Response: Increased immunogenicity in elderly population.
• Chronic Hepatitis B: Supports HBeAg seroconversion and viral suppression
• NK Cell Activation: Increased tumor cell clearance
• Antioxidant Effects: Reduced oxidative stress in tissues
• Sepsis Support: Improved monocyte function and reduced mortality
• Dendritic Cell Activation: Enhanced antigen presentation and immune priming
• Safety Profile: Minimal adverse effects; welltolerated in diverse populations

Specifications:

• Compound: Thymosin Alpha 1 (Tα1)
• Format: Research compound
• Use: Research use only